Business
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells\nKyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis\nEMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting on April 13.\n\n \n \n \n \n \n \n\n \nOf particular interest:\nOn April 15, Jeremias Motte, M.D., a senior physician and neurologist at the University Hospital in Bochum, Germany, will present a case study of a successful treatment of patients suffering from concomitant myasthenia gravis and Lambert-Eaton syndrome1On April 16, Kyverna will host a conference call discussing recent experience with KYV-101 in patients suffering from neurological autoimmune diseases. Call-in details will be published in advance on the company's website (ir.kyvernatx.com)On April 16, Marinos Dalakas, M.D., FAAN, a professor at the Thomas Jefferson University Hospitals and a neurology specialist, will discuss advances in the therapeutic algorithm for autoimmune neuromuscular disorders\"We welcome the publication of these reports from named-patient case studies that contribute to building confidence in the desired safety and efficacy profile for innovating CAR T-cell therapies,\" said Jeffrey Dunn, M.D., the Lily Sarafan director of Neuroimmunology and clinical professor and chief of Neuroimmunology within the Department of Neurology and Neurological Sciences at Stanford University in Palo Alto, California.\n\"We look forward to attending AAN and engaging with the scientific community in seeking to develop paradigm-shifting treatment options for patients living with autoimmune diseases,\" said Peter Maag, Ph.D., chief executive officer of Kyverna.\nChimeric antigen receptor (CAR) T-cell therapy involves modifying a patient's T cells to recognize and remove B cells in the patient's body. CD19 CAR T-cell therapy specifically targets CD19, a protein expressed on t...